Business Context and Reporting Period
This Form 8-K is a current report filed by Reviv3 Procare Company (noting the request metadata references "Axil Brands, Inc." which does not match the registrant name in the text) dated November 1, 2022. The filing reports a change in executive management effective November 1, 2022.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and compensation arrangements.
Material Changes
- Executive Appointment: Meenu Jain was appointed as Chief Financial Officer (CFO), succeeding Christopher Go.
- Role Transition: Christopher Go will continue to serve as Secretary of the Company.
- Compensation Structure: The new CFO's compensation includes a base salary of $140,000 per year and a stock option grant for 300,000 shares of common stock.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of general business risks. The employment agreement is "at-will," allowing either party to terminate employment at any time. The agreement includes standard confidentiality, non-competition, and non-solicitation restrictions for one year following termination.
Investor Verification Checklist
- Verify the correct registrant name (Reviv3 Procare Company) versus the metadata provided (Axil Brands, Inc.).
- Review the full text of the Executive Employment Agreement filed as Exhibit 10.1 for complete terms.
- Confirm the vesting schedule details for the 300,000 stock options granted to the new CFO.
- Check subsequent filings for any financial updates, as this 8-K contains no financial statements.